Myeloproliferative Neoplasms (MPN)

Rusfertide Poised to Transform Polycythemia Vera Care: Andrew Kuykendall, MD

Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD

Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD

Ruxolitinib Plus Anemia Supportive Care Maintains Efficacy in Myelofibrosis: Pankit Vachhani, MD

Next Steps for INCA33989 Focus on Dosing, Delivery, and Safety: John Mascarenhas, MD

Post-Hoc Analysis Evaluates Ruxolitinib Plus Anemia-Supportive Therapies in Myelofibrosis: Pankit Vachhani, MD

INCA33989 Shows Disease-Modifying Potential With Favorable Safety in Essential Thrombocythemia: John Mascarenhas, MD

Phase 1 Trials Assess Safety, Dosing of CAL-R Antibody for Essential Thrombocythemia: John Mascarenhas, MD

Rusfertide Offers Sustainable PV Management Strategy: Andrew Kuykendall, MD

Fatigue, Quality of Life Improve With Rusfertide: Andrew Kuykendall, MD